Fresenius Kabi Pharmaceuticals Holding, Inc. Release: APP Pharmaceuticals To Market Anastrozole Tablets In The U.S.  
6/29/2010 7:49:10 AM

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Fresenius Kabi Pharmaceuticals Holding, Inc., (NASDAQ:APCVZ) announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited (NSE:FKONCO) (BSE:532545). APP Pharmaceuticals and Fresenius Kabi Oncology Limited are members of the Fresenius Kabi Group of companies. Anastrozole is therapeutically equivalent to the reference-listed drug Arimidex®, which is currently marketed by the innovator AstraZeneca.